Geode Capital Management
ALGS icon

Geode Capital Management’s Aligos Therapeutics ALGS Stock Holding History

Geode Capital Management’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$272K Sell
47,173
-2,802
-6% -$17.3K ﹤0.01% 3814
2026
Q1 		$371K Buy
49,975
+2,234
+5% +$16.9K ﹤0.01% 3692
2025
Q4 		$445K Buy
47,741
+661
+1% +$6.23K ﹤0.01% 3625
2025
Q3 		$462K Buy
47,080
+13,032
+38% +$119K ﹤0.01% 3653
2025
Q2 		$246K Buy
34,048
+5,978
+21% +$35.8K ﹤0.01% 3806
2025
Q1 		$232K Buy
28,070
+817
+3% +$17.9K ﹤0.01% 3791
2024
Q4 		$1.09M Buy
27,253
+3,197
+13% +$61.8K ﹤0.01% 3344
2024
Q3 		$208K Buy
24,056
+7,828
+48% +$97.4K ﹤0.01% 3890
2024
Q2 		$142K Buy
16,228
+1,306
+9% +$23K ﹤0.01% 4029
2024
Q1 		$366K Buy
14,922
+2,080
+16% +$41.4K ﹤0.01% 3722
2023
Q4 		$213K Buy
12,842
+3,182
+33% +$54.7K ﹤0.01% 3918
2023
Q3 		$180K Sell
9,660
-604
-6% -$13.4K ﹤0.01% 4023
2023
Q2 		$249K Buy
10,264
+2,270
+28% +$60.9K ﹤0.01% 3945
2023
Q1 		$175K Hold
7,994
– – ﹤0.01% 4118
2022
Q4 		$190K Buy
7,994
+377
+5% +$9.5K ﹤0.01% 4128
2022
Q3 		$209K Hold
7,617
– – ﹤0.01% 4184
2022
Q2 		$230K Sell
7,617
-6,574
-46% -$223K ﹤0.01% 4175
2022
Q1 		$762K Buy
14,191
+208
+1% +$16.7K ﹤0.01% 3732
2021
Q4 		$4.15M Buy
13,983
+1,437
+11% +$524K ﹤0.01% 2997
2021
Q3 		$4.86M Buy
12,546
+2,332
+23% +$922K ﹤0.01% 2926
2021
Q2 		$5.21M Buy
10,214
+3,064
+43% +$1.95M ﹤0.01% 2873
2021
Q1 		$4.06M Buy
7,150
+2
+0% +$1.33K ﹤0.01% 2891
2020
Q4 		$4.94M Buy
+7,148
New +$3.48M ﹤0.01% 2611

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management's ALGS Position: Q2 2026 in Review

Geode Capital Management reduced its Aligos Therapeutics (ALGS) stake by 5.6% in Q2 2026, selling an estimated $17.3K and leaving 47,173 shares worth $272K. The position accounts for ﹤0.01% of the portfolio, ranked #3814.

Geode Capital Management first reported a position in ALGS in Q4 2020 and has held it in 23 quarters since. The position peaked at $5.21M in Q2 2021. 29 funds tracked by Wall St. Rank hold ALGS as of Q2 2026.

  • Geode Capital Management held 47,173 shares of Aligos Therapeutics worth $272K as of Q2 2026.
  • Geode Capital Management sold 2,802 Aligos Therapeutics shares in Q2 2026, an estimated $17.3K.
  • Aligos Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3814 holding.
  • Geode Capital Management first reported a position in Aligos Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Geode Capital Management's Aligos Therapeutics position peaked at $5.21M in Q2 2021.
  • 29 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.